Down-regulation of hepatic expression of GHR/STAT5/IGF-1 signaling pathway fosters development and aggressiveness of HCV-related hepatocellular carcinoma: Crosstalk with Snail-1 and type 2 transforming growth factor-beta receptor.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 08 08 2021
accepted: 24 10 2022
entrez: 14 11 2022
pubmed: 15 11 2022
medline: 18 11 2022
Statut: epublish

Résumé

So far, few clinical trials are available concerning the role of growth hormone receptor (GHR)/signal transducer and activator of transcription 5 (STAT5)/insulin like growth factor-1 (IGF-1) axis in hepatocarcinogenesis. The aim of this study was to evaluate the hepatic expression of GHR/STAT5/IGF-1 signaling pathway in hepatocellular carcinoma (HCC) patients and to correlate the results with the clinico-pathological features and disease outcome. The interaction between this signaling pathway and some inducers of epithelial-mesenchymal transition (EMT), namely Snail-1 and type 2 transforming growth factor-beta receptor (TGFBR2) was studied too. A total of 40 patients with HCV-associated HCC were included in this study. They were compared to 40 patients with HCV-related cirrhosis without HCC, and 20 healthy controls. The hepatic expression of GHR, STAT5, IGF-1, Snail-1 and TGFBR2 proteins were assessed by immunohistochemistry. Compared with cirrhotic patients without HCC and healthy controls, cirrhotic patients with HCC had significantly lower hepatic expression of GHR, STAT5, and IGF-1proteins. They also displayed significantly lower hepatic expression of TGFBR2, but higher expression of Snail-1 versus the non-HCC cirrhotic patients and controls. Serum levels of alpha-fetoprotein (AFP) showed significant negative correlations with hepatic expression of GHR (r = -0.31; p = 0.029) and STAT5 (r = -0.29; p = 0.04). Hepatic expression of Snail-1 also showed negative correlations with GHR, STAT5, and IGF-1 expression (r = -0.55, p = 0.02; r = -0.472, p = 0.035, and r = -0.51, p = 0.009, respectively), whereas, hepatic expression of TGFBR2 was correlated positively with the expression of all these proteins (r = 0.47, p = 0.034; 0.49, p = 0.023, and r = 0.57, p<0.001, respectively). Moreover, we reported that decreased expression of GHR was significantly associated with serum AFP level>100 ng/ml (p = 0.048), increased tumor size (p = 0.02), vascular invasion (p = 0.002), and advanced pathological stage (p = 0.01). Similar significant associations were found between down-regulation of STAT5 expression and AFP level > 100 ng/ml (p = 0.006), vascular invasion (p = 0.009), and advanced tumor stage (p = 0.007). Also, attenuated expression of IGF-1 showed a significant association with vascular invasion (p < 0.001). Intriguingly, we detected that lower expression of GHR, STAT5 and IGF-1 were considered independent predictors for worse outcome in HCC. Decreased expression of GHR/STAT5/IGF-1 signaling pathway may have a role in development, aggressiveness, and worse outcome of HCV-associated HCC irrespective of the liver functional status. Snail-1 and TGFBR2 as inducers of EMT may be key players. However, large prospective multicenter studies are needed to validate these results.

Sections du résumé

BACKGROUND AND AIMS
So far, few clinical trials are available concerning the role of growth hormone receptor (GHR)/signal transducer and activator of transcription 5 (STAT5)/insulin like growth factor-1 (IGF-1) axis in hepatocarcinogenesis. The aim of this study was to evaluate the hepatic expression of GHR/STAT5/IGF-1 signaling pathway in hepatocellular carcinoma (HCC) patients and to correlate the results with the clinico-pathological features and disease outcome. The interaction between this signaling pathway and some inducers of epithelial-mesenchymal transition (EMT), namely Snail-1 and type 2 transforming growth factor-beta receptor (TGFBR2) was studied too.
MATERIAL AND METHODS
A total of 40 patients with HCV-associated HCC were included in this study. They were compared to 40 patients with HCV-related cirrhosis without HCC, and 20 healthy controls. The hepatic expression of GHR, STAT5, IGF-1, Snail-1 and TGFBR2 proteins were assessed by immunohistochemistry.
RESULTS
Compared with cirrhotic patients without HCC and healthy controls, cirrhotic patients with HCC had significantly lower hepatic expression of GHR, STAT5, and IGF-1proteins. They also displayed significantly lower hepatic expression of TGFBR2, but higher expression of Snail-1 versus the non-HCC cirrhotic patients and controls. Serum levels of alpha-fetoprotein (AFP) showed significant negative correlations with hepatic expression of GHR (r = -0.31; p = 0.029) and STAT5 (r = -0.29; p = 0.04). Hepatic expression of Snail-1 also showed negative correlations with GHR, STAT5, and IGF-1 expression (r = -0.55, p = 0.02; r = -0.472, p = 0.035, and r = -0.51, p = 0.009, respectively), whereas, hepatic expression of TGFBR2 was correlated positively with the expression of all these proteins (r = 0.47, p = 0.034; 0.49, p = 0.023, and r = 0.57, p<0.001, respectively). Moreover, we reported that decreased expression of GHR was significantly associated with serum AFP level>100 ng/ml (p = 0.048), increased tumor size (p = 0.02), vascular invasion (p = 0.002), and advanced pathological stage (p = 0.01). Similar significant associations were found between down-regulation of STAT5 expression and AFP level > 100 ng/ml (p = 0.006), vascular invasion (p = 0.009), and advanced tumor stage (p = 0.007). Also, attenuated expression of IGF-1 showed a significant association with vascular invasion (p < 0.001). Intriguingly, we detected that lower expression of GHR, STAT5 and IGF-1 were considered independent predictors for worse outcome in HCC.
CONCLUSION
Decreased expression of GHR/STAT5/IGF-1 signaling pathway may have a role in development, aggressiveness, and worse outcome of HCV-associated HCC irrespective of the liver functional status. Snail-1 and TGFBR2 as inducers of EMT may be key players. However, large prospective multicenter studies are needed to validate these results.

Identifiants

pubmed: 36374927
doi: 10.1371/journal.pone.0277266
pii: PONE-D-21-25660
pmc: PMC9662744
doi:

Substances chimiques

Receptors, Somatotropin 0
STAT5 Transcription Factor 0
Insulin-Like Growth Factor I 67763-96-6
alpha-Fetoproteins 0
Receptors, Transforming Growth Factor beta 0
Receptor, Transforming Growth Factor-beta Type II EC 2.7.11.30
Transforming Growth Factors 76057-06-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0277266

Informations de copyright

Copyright: © 2022 Abu El-Makarem et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Gut. 2015 May;64(5):830-41
pubmed: 25681399
Cancer. 2005 Jul 1;104(1):44-52
pubmed: 15895377
Leukemia. 2019 Jul;33(7):1583-1597
pubmed: 30679796
J Hepatol. 1998 Oct;29(4):559-64
pubmed: 9824264
Nature. 2003 Oct 9;425(6958):577-84
pubmed: 14534577
Domest Anim Endocrinol. 2002 Jul;23(1-2):351-60
pubmed: 12142251
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1548-55
pubmed: 25773877
Sci Rep. 2018 Jan 26;8(1):1661
pubmed: 29374178
Nat Rev Cancer. 2019 Feb;19(2):82-96
pubmed: 30578415
J Physiol Biochem. 2017 May;73(2):245-258
pubmed: 28124277
Br J Cancer. 2013 Jul 9;109(1):83-91
pubmed: 23756865
Nat Rev Cancer. 2010 Jun;10(6):415-24
pubmed: 20495575
Hum Pathol. 2013 Mar;44(3):310-9
pubmed: 23026195
J Cell Sci. 2013 Aug 1;126(Pt 15):3333-43
pubmed: 23704351
Free Radic Res. 2014 Jul;48(7):806-13
pubmed: 24684482
Gastroenterology. 2016 Apr;150(4):835-53
pubmed: 26795574
Cancers (Basel). 2014 Aug 13;6(3):1670-90
pubmed: 25125485
Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13331-6
pubmed: 17690250
Hepatology. 2001 Feb;33(2):464-70
pubmed: 11172350
Growth Horm IGF Res. 2014 Feb;24(1):29-34
pubmed: 24382376
Sci Rep. 2016 Sep 02;6:31963
pubmed: 27585821
Hepatogastroenterology. 2003 May-Jun;50(51):814-6
pubmed: 12828091
Contemp Oncol (Pozn). 2012;16(3):234-9
pubmed: 23788886
N Engl J Med. 1962 Jan 4;266:31-5
pubmed: 14038540
Science. 1998 Jan 23;279(5350):563-6
pubmed: 9438850
Biochemistry (Mosc). 2017 Aug;82(8):861-873
pubmed: 28941454
J Clin Oncol. 2011 Jun 20;29(18):2448-58
pubmed: 21576635
J Hepatol. 2002 Jun;36(6):751-8
pubmed: 12044524
Cancers (Basel). 2019 Jan 07;11(1):
pubmed: 30621055
J Exp Clin Cancer Res. 2018 Apr 27;37(1):89
pubmed: 29699590
J Hepatocell Carcinoma. 2018 Nov 08;5:99-108
pubmed: 30519546
J Exp Med. 2009 Apr 13;206(4):819-31
pubmed: 19332876
J Clin Endocrinol Metab. 2001 Jul;86(7):2935-41
pubmed: 11443146
Sci Rep. 2021 Jan 14;11(1):1372
pubmed: 33446803
Results Probl Cell Differ. 2006;41:47-75
pubmed: 16909890
J Biol Chem. 1982 May 10;257(9):5038-45
pubmed: 6279656
Dig Dis Sci. 2013 Sep;58(9):2721-8
pubmed: 23703450
BMC Gastroenterol. 2019 May 2;19(1):66
pubmed: 31046687
Cell Biosci. 2011 Aug 31;1:29
pubmed: 21880137
Hepatology. 1996 Aug;24(2):289-93
pubmed: 8690394
Gastroenterology. 2015 Oct;149(4):1053-67.e14
pubmed: 26065367
Semin Cancer Biol. 2011 Apr;21(2):139-46
pubmed: 21251983
Clin Mol Hepatol. 2021 Apr;27(2):313-328
pubmed: 33317258
Ai Zheng. 2003 Mar;22(3):298-301
pubmed: 12654191
Mol Cell Endocrinol. 2012 Sep 25;361(1-2):1-11
pubmed: 22564914
Carcinogenesis. 2014 Jun;35(6):1330-40
pubmed: 24464786
Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a003129
pubmed: 20457567
Int J Oncol. 2015 Feb;46(2):587-96
pubmed: 25405790
Cancer Res. 2008 Jun 15;68(12):4525-30
pubmed: 18559496
Sci Rep. 2017 Feb 14;7:41670
pubmed: 28195144
Breast Cancer Res. 2021 Nov 7;23(1):104
pubmed: 34743736
Nat Rev Cancer. 2009 Nov;9(11):798-809
pubmed: 19851315
Oncogene. 2006 Jun 26;25(27):3787-800
pubmed: 16799620
Cell. 1999 Aug 6;98(3):295-303
pubmed: 10458605
Lab Invest. 2010 Sep;90(9):1339-45
pubmed: 20531292
Gastroenterol Hepatol (N Y). 2017 Jul;13(7):398-410
pubmed: 28867968
Cancer Lett. 2015 Jan 28;356(2 Pt B):713-20
pubmed: 25449435
Oncol Rep. 2015 Apr;33(4):1872-82
pubmed: 25653024
JCI Insight. 2019 Feb 7;4(3):
pubmed: 30728323
Endocr Rev. 2001 Feb;22(1):53-74
pubmed: 11159816
J Natl Cancer Inst. 2014 May 09;106(5):
pubmed: 24815863
World J Gastroenterol. 2005 Jul 21;11(27):4272-6
pubmed: 16015705
Oncogene. 2018 Apr;37(14):1857-1868
pubmed: 29348460
Lancet. 2002 Jul 27;360(9329):273-7
pubmed: 12147369
Curr Biol. 1996 May 1;6(5):606-13
pubmed: 8805279
Hepatoma Res. 2019;5:
pubmed: 31701016
Virol J. 2011 Nov 01;8:496
pubmed: 22044490
Hepatology. 2008 Sep;48(3):978-90
pubmed: 18712788
Oncotarget. 2017 Jul 12;8(46):81098-81108
pubmed: 29113370
Hepatobiliary Pancreat Dis Int. 2008 Aug;7(4):406-11
pubmed: 18693177
J Clin Endocrinol Metab. 1997 Apr;82(4):1210-9
pubmed: 9100598
Oncogene. 2013 Aug 1;32(31):3587-97
pubmed: 22926520
Semin Liver Dis. 2019 May;39(2):111-123
pubmed: 30912097
Gastroenterology. 2017 Nov;153(5):1378-1391.e6
pubmed: 28734833
J Clin Endocrinol Metab. 2013 Feb;98(2):E304-8
pubmed: 23316084
Cancer Res. 2006 Oct 15;66(20):9948-56
pubmed: 17047057
Curr Opin Gastroenterol. 2009 May;25(3):186-94
pubmed: 19387255
Lung Cancer. 2007 Oct;58(1):36-43
pubmed: 17566598
Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1267-72
pubmed: 23288901
J Virol. 2012 Jun;86(11):6315-22
pubmed: 22457523
Eur J Cancer. 2000 Aug;36(13 Spec No):1607-20
pubmed: 10959047
Arch Endocrinol Metab. 2019 Nov-Dec;63(6):568-575
pubmed: 31939481
J Clin Invest. 2005 Feb;115(2):209-18
pubmed: 15690074
Eur J Pharmacol. 2014 Jan 15;723:156-66
pubmed: 24333218
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Hepatology. 2015 Oct;62(4):1160-73
pubmed: 26154152
FEBS Lett. 2010 Jun 3;584(11):2231-6
pubmed: 20385133
Oncotarget. 2017 Dec 05;8(67):111922-111930
pubmed: 29340101
Gastroenterology. 2004 Feb;126(2):529-40
pubmed: 14762790
J Clin Invest. 2008 Oct;118(10):3331-42
pubmed: 18802480
Clin Gastroenterol Hepatol. 2012 Feb;10(2):117-25
pubmed: 21893127
J Transl Med. 2016 Jan 06;14:3
pubmed: 26733412
World J Gastroenterol. 2016 Jun 21;22(23):5384-92
pubmed: 27340354
Onco Targets Ther. 2021 Jan 28;14:725-736
pubmed: 33536764
Nat Rev Cancer. 2002 Jun;2(6):442-54
pubmed: 12189386
Gastroenterology. 1994 Dec;107(6):1805-11
pubmed: 7958695
Cancer Cell. 2012 Dec 11;22(6):725-36
pubmed: 23201165
J Clin Lab Anal. 2010;24(3):195-200
pubmed: 20486202
Oncol Rep. 2013 Sep;30(3):1337-45
pubmed: 23784592
Hepatology. 1984 Jan-Feb;4(1 Suppl):3S-6S
pubmed: 6319264
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
Clin Cancer Res. 2013 Oct 15;19(20):5658-74
pubmed: 23942095
J Hepatol. 2020 Jan;72(1):104-118
pubmed: 31541681
Biochim Biophys Acta. 2011 Jan;1815(1):104-14
pubmed: 20969928
South Asian J Cancer. 2018 Jan-Mar;7(1):24-26
pubmed: 29600229
J Biol Chem. 1999 Oct 15;274(42):29874-82
pubmed: 10514468
Am J Cancer Res. 2018 Feb 01;8(2):302-316
pubmed: 29511600
Endocrinology. 2012 Jan;153(1):283-94
pubmed: 22028448
Hepatology. 2011 May;53(5):1427-9
pubmed: 21452287
Cell Growth Differ. 2002 Mar;13(3):115-22
pubmed: 11959812
Cancer Med. 2019 Mar;8(3):1054-1065
pubmed: 30791221
World J Gastroenterol. 2004 Sep 15;10(18):2740-3
pubmed: 15309731
J Virol. 2009 Dec;83(23):12590-600
pubmed: 19793824
World J Hepatol. 2020 Nov 27;12(11):883-896
pubmed: 33312416
Fukuoka Igaku Zasshi. 2013 Oct;104(10):334-8
pubmed: 24511663
Hepatology. 1990 Jan;11(1):123-6
pubmed: 2153093
Cancer Res. 1989 Apr 1;49(7):1773-7
pubmed: 2466561
Am J Surg. 1999 Mar;177(3):209-15
pubmed: 10219856
PLoS One. 2011;6(10):e26637
pubmed: 22039521
Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):699-704
pubmed: 15767352
Oncotarget. 2017 Oct 10;8(61):103900-103918
pubmed: 29262609
Int J Cancer. 2012 Jul 15;131(2):512-7
pubmed: 21898383
Growth Horm IGF Res. 2015 Aug;25(4):174-81
pubmed: 26068014
Clin Endocrinol (Oxf). 2006 Feb;64(2):115-21
pubmed: 16430706
Endocrine. 2000 Jun;12(3):265-71
pubmed: 10963047
Clin Cancer Res. 2006 Jan 1;12(1):11-9
pubmed: 16397018
Hepatology. 2012 Mar;55(3):941-52
pubmed: 22031092
Int J Mol Sci. 2017 Jun 15;18(6):
pubmed: 28617312
Hepatology. 2011 Mar;53(3):1020-2
pubmed: 21374666
Mol Cancer Ther. 2004 Sep;3(9):1159-65
pubmed: 15367710
Endocrinology. 2008 May;149(5):2433-42
pubmed: 18187555
Mediators Inflamm. 2016;2016:6058147
pubmed: 26966341
Mol Cell Endocrinol. 2020 Dec 1;518:111003
pubmed: 32919021
Oncotarget. 2016 May 17;7(20):29465-79
pubmed: 27102295
Front Endocrinol (Lausanne). 2018 Apr 09;9:117
pubmed: 29686648
Int J Cancer. 2003 Dec 20;107(6):873-7
pubmed: 14601044
Hepatology. 2012 Dec;56(6):2375-86
pubmed: 22711600
Clin Cancer Res. 2006 Dec 1;12(23):7140-8
pubmed: 17145839
Clin Exp Nephrol. 2010 Oct;14(5):440-4
pubmed: 20567872
Semin Liver Dis. 1992 Aug;12(3):265-78
pubmed: 1439879

Auteurs

Mona A Abu El-Makarem (MA)

Department of Internal Medicine, School of Medicine, Minia University, Minia, Egypt.

Mariana F Kamel (MF)

Department of Pathology, School of Medicine, Minia University, Minia, Egypt.
Department of Pathology, Minia Oncology Center, Minia, Egypt.

Ahmed A Mohamed (AA)

Department of Internal Medicine, School of Medicine, Minia University, Minia, Egypt.

Hisham A Ali (HA)

Department of Internal Medicine, School of Medicine, Minia University, Minia, Egypt.

Mahmoud R Mohamed (MR)

Department of Internal Medicine, School of Medicine, Minia University, Minia, Egypt.

Alaa El-Deen M Mohamed (AEM)

Department of Internal Medicine, School of Medicine, Minia University, Minia, Egypt.

Ahmed M El-Said (AM)

Department of Internal Medicine, School of Medicine, Minia University, Minia, Egypt.

Mahmoud G Ameen (MG)

Department of Pathology, South Egypt Cancer Institute, Assuit University, Assuit, Egypt.

Alshymaa A Hassnine (AA)

Department of Tropical Medicine and Gastroenterology, School of Medicine, Minia University, Minia, Egypt.

Hatem A Hassan (HA)

Department of Internal Medicine, School of Medicine, Minia University, Minia, Egypt.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH